Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 84Lymphoma, Follicular 46Lymphoma, Non-Hodgkin 36Lymphoma, Large B-Cell, Diffuse 28Lymphoma 28Lymphoma, Mantle-Cell 26Lymphoma, B-Cell, Marginal Zone 21Lymphoma, B-Cell 17Recurrence 13Neoplasms 11Leukemia 7Leukemia, B-Cell 5Burkitt Lymphoma 5Leukemia, Hairy Cell 4Neoplasm, Residual 3Melanoma 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Disease 2Dendritic Cell Sarcoma, Interdigitating 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bronchiolitis Obliterans Syndrome 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Tumor Lysis Syndrome 1Solid Cancers 1

Interventions

Rituximab 12Cyclophosphamide 12fludarabine 8dacetuzumab 7blinatumomab 6Tacrolimus 6Busulfan 6Vincristine 5Prednisone 5Etoposide 5Doxorubicin 5Bortezomib 5fludarabine phosphate 4Valganciclovir 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Epoetin Alfa 4venetoclax 3ibrutinib 3Whole-Body Irradiation 3Methotrexate 3Melphalan 3Lenalidomide 3Ganciclovir 3Everolimus 3Dexamethasone 3Darbepoetin alfa 3Alemtuzumab 3tetulomab tetraxetan lu-177 2ponatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoproliferative Disorders × obinutuzumab × Clear all
NCT04883437 2026-02-09

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Emory University

Phase 2 Recruiting
49 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoproliferative Disorders, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡